Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial

OBJECTIVE: The risks of cardio-renal complications of diabetes increase with age. In the EMPA-REG OUTCOME® trial, empagliflozin reduced cardiovascular (CV) mortality by 38% in patients with type 2 diabetes (T2D) and CV disease. Here we compare outcomes with empagliflozin in older patients in EMPA-RE...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Age Ageing
Hlavní autoři: Monteiro, Pedro, Bergenstal, Richard M, Toural, Elvira, Inzucchi, Silvio E, Zinman, Bernard, Hantel, Stefan, Kiš, Sanja Giljanovic, Kaspers, Stefan, George, Jyothis T, Fitchett, David
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7963112/
https://ncbi.nlm.nih.gov/pubmed/31579904
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ageing/afz096
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky